In the news: Fusion Pharmaceuticals. The background image is a woman researcher working in a lab while wearing personal protective equipment (PPE).

Hamilton’s Fusion Pharmaceuticals Raises $26 Million CAD


This article originally appeared on written by Isabelle Kirkwood.  For the original post please click this link.

Biopharmaceutical precision oncology startup Fusion Pharmaceuticals has received a commitment of up to $26 million CAD ($20 million USD) from the Canada Pension Plan Investment Board (CPPIB).

This funding comes ten months after Fusion Pharmaceuticals’ $140 million CAD Series B. The startup said the net-new capital will be used to expand the use of its platform that connects medical isotopes to targeting molecules which it says can create novel cancer treatments. It plans to expand the platform by investing in new partnerships as well as targeting molecules that could lead to new treatments.

Funds will also be put toward the company’s lead clinical candidate, FPI-1434, currently in a Phase 1 trial for treating solid tumours. FPI-1434, which Fusion Pharmaceuticals has called its “linker technology,” is intended to combine the precision targeting of an antibody with the potency of alpha-particle emitting medical isotopes. This, the company claims, helps to attack and eradicate cancer cells across multiple tumour types.

Founded in 2014 at McMaster University in Hamilton, Ont., Fusion Pharmaceuticals’ goal is to cure cancer by developing targeted alpha therapeutics, a method that employs radioactive substances that undergo radioactive decay to treat diseased tissue at close proximity.

The company views this approach as the “next generation” of radiation therapy, promoting it as a potentially safer and more effective therapy than currently available options.

The CPPIB is an investment management organization that invests the funds of the Canada Pension Plan on behalf of its 20 million Canadian contributors and beneficiaries. The organization holds investments in private equity, public equity holdings, and real estate in 52 countries. Last year, the CPPIB committed capital to Northleaf’s $300 million fund-of-funds.

“The additional capital provides opportunities for Fusion Pharmaceuticals to accelerate our growth plans and our pipeline of novel and combination therapy assets that can deliver effective and personalized radiation therapies to cancer patients,” said Fusion Pharmaceuticals CEO John Valliant.

Share this article
View All Categories

Featured iF Clients

14th Annual LiONS LAIR Pitch Competition and in-person Gala on September 26, 2024 from 5:00pm to 9:00pm. Tickets available on

Attend the 14th annual LiONS LAIR pitch competition

Since 2011, Innovation Factory’s LiONS LAIR has helped more than 150 startups launch and scale their businesses. This fall, join over 350 entrepreneurs, investors and thought leaders to network over dinner and drinks, celebrate innovation, and watch finalists pitch live to a panel of judges to win cash and in-kind prizes.

When: September 26, 2024 | 5:00pm – 9:00pm 

Where: LiUNA Station – 360 James St. N, Hamilton, Ontario L8L 1H5

Celebrate BIG ideas that make a bigger impact at The Big DiF, Innovation Factory’s annual open house and client showcase. Join 250+ people from the Hamilton-Halton community to celebrate entrepreneurship and innovation.

Join Innovation Factory's Annual Open House - The Big DiF!

Network with 250+ industry professionals, discover emerging solutions from our innovators, and celebrate entrepreneurship within the Hamilton-Halton ecosystem.

May 9, 2024 | 4:00pm – 8:00pm | Hamilton, Ontario